摘要
目的观察分析脂必泰胶囊在膜性肾病患者治疗中的临床效果。方法60例膜性肾病患者,按随机数字表法分为观察组和对照组,各30例。对照组给予盐酸贝那普利片治疗,观察组在对照组基础上联合应用脂必泰胶囊治疗。比较两组治疗前后的24 h尿蛋白定量、血清白蛋白(Alb)、血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、超敏C反应蛋白(hs-CRP)]、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]、不良反应发生情况。结果治疗后,两组24 h尿蛋白定量较治疗前降低,Alb较治疗前升高,且观察组24 h尿蛋白定量(1.93±0.29)g/24 h低于对照组的(2.70±0.34)g/24 h,Alb(38.23±1.53)g/L高于对照组的(33.90±1.52)g/L,差异有统计学意义(P<0.05)。治疗后,观察组TG、TC、LDL-C较治疗前降低,HDL-C较治疗前增高,差异有统计学意义(P<0.05);观察组TG、TC、LDL-C分别为(1.95±0.36)、(4.65±0.68)、(3.34±0.35)mmol/L,均低于对照组的(2.45±0.42)、(6.11±0.54)、(4.25±0.34)mmol/L,HDL-C(1.35±0.23)mmol/L高于对照组的(1.14±0.15)mmol/L,差异均有统计学意义(P<0.05)。治疗后,观察组IL-6、IL-8、hs-CRP较治疗前降低,差异有统计学意义(P<0.05);观察组IL-6、IL-8、hs-CRP分别为(22.54±3.78)pg/ml、(4.01±0.62)pg/ml、(5.90±1.13)mg/L,均低于对照组的(29.50±4.05)pg/ml、(5.30±0.60)pg/ml、(9.90±1.26)mg/L,差异有统计学意义(P<0.05)。治疗后,观察组MDA较治疗前降低,SOD、GSH-Px较治疗前升高,差异有统计学意义(P<0.05);观察组MDA(16.72±5.25)μmol/L低于对照组的(24.98±5.20)μmol/L,SOD(120.42±21.44)kU/L、GSH-Px(138.02±19.70)mg/L高于对照组的(84.25±20.02)kU/L、(127.51±20.90)mg/L,差异有统计学意义(P<0.05)。治疗过程中无患者脱落,两组无严重不良反应出现。结论脂必泰联合贝那普利片可有效控制膜性肾病患者的蛋白尿及血脂水平,同时降低炎症因子及氧化应激反应。
Objective To observe and analyze the clinical effect of Zhibitai capsules in membranous nephropathy.Methods A total of 60 patients with membranous nephropathy were divided into observation group and control group according to the random numerical table,with 30 cases in each group.The control group was treated with benazepril hydrochloride tablets,and the observation group was treated with Zhibitai capsules on the basis of the control group.Both groups were compared in terms of 24 h urinary protein quantification,serum albumin(Alb),blood lipids[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C)],inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),high-sensitivity C-reactive protein(hs-CRP)],oxidative stress indicators[superoxide dismutase(SOD),malondialdehyde(MDA),glutathione peroxidase(GSH-Px)]before and after treatment,and occurrence of adverse reactions.Results After treatment,the 24-h urinary protein quantification was lower and Alb was higher in both groups compared to those before treatment;the 24-h urinary protein quantification(1.93±0.29)g/24 h in the observation group was lower than(2.70±0.34)g/24 h in the control group,and Alb(38.23±1.53)g/L was higher than(33.90±1.52)g/L in the control group;all differences were statistically significant(P<0.05).After treatment,the TG,TC and LDL-C were lower and HDL-C was higher in the observation group compared with those before treatment,and the differences were statistically significant(P<0.05).The TG,TC and LDL-C of the observation group were(1.95±0.36),(4.65±0.68),(3.34±0.35)mmol/L,which were lower than(2.45±0.42),(6.11±0.54),(4.25±0.34)mmol/L of the control group,and the HDL-C(1.35±0.23)mmol/L was higher than(1.14±0.15)mmol/L of the control group.All differences were statistically significant(P<0.05).After treatment,the IL-6,IL-8 and hs-CRP in the observation group were lower than those in this group before treatment,and the difference was statistically significant(P<0.05).The IL-6,IL-8 and hs-CRP(22.54±3.78)pg/ml,(4.01±0.62)pg/ml,and(5.90±1.13)mg/L in the observation group were lower than(29.50±4.05)pg/ml,(5.30±0.60)pg/ml,and(9.90±1.26)mg/L in the control group,and the difference was statistically significant(P<0.05).After treatment,the MDA of the observation group was lower than that before treatment,and the SOD and GSH-Px were higher than those before treatment.All differences were statistically significant(P<0.05).The MDA(16.72±5.25)μmol/L of the observation group was lower than(24.98±5.20)μmol/L of the control group,and the SOD(120.42±21.44)μU/L and GSH-Px(138.02±19.70)mg/L were higher than(84.25±20.02)μU/L and(127.51±20.90)mg/L of the control group.All differences were statistically significant(P<0.05).No drop-out cases during the treatment,and no serious adverse reactions occurred in both groups.Conclusion Zhibitai capsules in combination with benazepril tablets can effectively control urine protein and lipid levels in patients with membranous nephropathy,while reducing inflammatory factors and oxidative stress.
作者
孔爱丽
仇晓玲
KONG Ai-li;QIU Xiaoling(Department of Nephrology,Huludao Central Hospital,Huludao 125001,China)
出处
《中国实用医药》
2021年第36期18-21,共4页
China Practical Medicine
关键词
脂必泰
贝那普利
膜性肾病
高脂血症
炎性因子
氧化应激
Zhibitai capsules
Benazepril
Membranous nephropathy
Hyperlipidemia
Inflammatory factors
Oxidative stress
